Q-omics provides the consensus-scored MEIOC profile across patient tissues and cancer cell-line models. MEIOC expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MEIOC is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MEIOC RNA expression shows 19,412 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where MEIOC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEIOC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEIOC survival associations across molecular data types. MEIOC RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEIOC RNA expression–survival associations across cancer types. High MEIOC expression shows unfavorable associations in MESO, LGG, UVM and UCEC, but favorable associations in READ and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for MEIOC RNA expression.
This table summarizes MEIOC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MEIOC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEIOC shows lower tumor expression in KIRC, THCA and KIRP and higher tumor expression in HNSC, UCEC and COAD. The KIRC box plot shows higher MEIOC RNA expression in normal versus tumor tissue (log2 FC = −0.456, t-test p < 0.001).
This table shows molecular features associated with MEIOC in patient tissues and cancer cell lines. In patient samples, MEIOC shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MEIOC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
